Back to top

Analyst Blog

Isis Pharmaceuticals, Inc. (ISIS - Analyst Report) recently announced that it has invested $3 million in biopharma company Regulus Therapeutics Inc.’s (RGLS - Snapshot Report) common stock at the latter’s initial public offering. Isis Pharma currently holds approximately 18% (7 million shares) of Regulus’ common stock on a fully diluted basis.

Regulus, founded by Alnylam Pharmaceuticals (ALNY - Analyst Report) and Isis Pharma, announced the pricing of its initial public offering earlier this month. Regulus offered 11.25 million shares of its common stock at $4.00 per share. Regulus started trading on NASDAQ from October 4, 2012.

We note that apart from Isis Pharma, AstraZeneca (AZN - Analyst Report) has purchased 6.25 million shares of Regulus at the initial public offer price. In August 2012, Regulus had filed a registration statement with the US Securities and Exchange Commission (SEC) regarding the initial public offering of its shares.

In the filing, Regulus indicated that Sanofi (SNY - Analyst Report) and GlaxoSmithKline (GSK - Analyst Report) have shown an interest in buying Regulus’s common stock, worth up to $10 million and $2 million, respectively, at the initial public offering price.

In September 2007, Alnylam and Isis Pharma joined forces to establish Regulus, a company focused on microRNA (mRNA) therapeutics. In October 2010, Sanofi made an equity investment in the company. As of June 30, 2012, Regulus was jointly owned by Alnylam (45%), Isis Pharma (46%) and Sanofi (9%).

Regulus is evaluating microRNA therapeutics in several areas including oncology, fibrosis, hepatitis C virus infection, multiple sclerosis and atherosclerosis. The company has collaborated with several companies including Glaxo, Sanofi, AstraZeneca and Biogen Idec (BIIB - Analyst Report) for microRNA therapeutics.

Our Recommendation

Currently, we have a Neutral recommendation on both Isis Pharma and Alnylam. Both companies carry a short-term Zacks #3 Rank (Hold rating).
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.35 +4.82%
CENTURY ALU… CENX 22.42 +3.99%
ERBA DIAGNO… ERB 2.90 +3.94%
MALLINCKROD… MNK 71.88 +3.41%
GTT COMMUNI… GTT 12.03 +3.26%